Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05052853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Feb 7, 2023, no change to tracked fieldsv3-v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2021 to Nov 1, 2021
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.
Trial Details
NCT Number NCT05052853
Lead Sponsor China Medical University Hospital
Conditions
(from sponsor)		 Prodromal Schizophrenia
Related terms Schizophrenia, Schizotypal Personality Disorder
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov